Starpharma readies US NDA for VivaGel® on positive results in Phase 3 Bacterial vaginosis

9 August 2017

Biotech trade publication noted Starpharma expects to file an NDA for VivaGel® BV for prevention of recurrent bacterial vaginosis (rBV) with the US FDA following the positive results of the Phase 3 trials.

Go to article

About Starpharma

This document contains Forward Looking Statements

For Further Information

© Starpharma Holdings Limited 2017